MANAGING THE COST OF GLAUCOMA TREATMENT

LUMIGAN® 0.01% is covered by many insurance companies and Medicare. In this section, we’ll review some of the basics about insurance coverage and how to keep an eye on your costs, including how to get assistance if you are unable to pay for your medication. There is also a
point-of-sale rebate available for LUMIGAN® 0.01% ophthalmic solution. If you have not signed up for this helpful rebate yet, click here. Please note that limitations apply—see rebate for details.

Commercial insurance versus Medicare

There are two types of insurance that you may have:

  • Commercial or private insurance: This type of medical insurance is usually provided by your employer, or you may pay for this insurance yourself (self-insured). Your coverage generally includes prescriptions.
  • Medicare: Medicare is provided by the US government to seniors and younger adults who meet certain criteria (for example, people with disabilities also rely on Medicare). Prescription drug coverage is provided under the Medicare Part D program. For more information about Medicare coverage, including available prescription drug plans, visit www.Medicare.gov.

What you pay at the pharmacy: your "co-pay"

Co-pays are the amount you have to pay for prescriptions once you have met your deductible. The amount you pay depends on the list of drugs that your insurance company covers. This list is called a “formulary.” Insurance companies categorize drugs into tiers based on cost and other considerations.

Drugs in the first 2 tiers are referred to as "preferred status" or "preferred tier" drugs, and usually have a lower co-pay—which means fewer out-of-pocket expenses for you.

Different brands within the same class of drugs may have different co-pays based on their formulary status. Co-pays are an important consideration when selecting a glaucoma treatment. Formularies are different among insurance plans, so it’s a good idea to ask your eye doctor, call your insurance company, or visit www.fingertipformulary.com to learn more.

Patient-assistance programs

Allergan, the maker of LUMIGAN® 0.01%, participates in RxHope®, which helps eligible, low-income US residents obtain free or low-cost prescriptions. RxHope® is supported by both the Pharmaceutical Research and Manufacturers of America (PhRMA) and participating pharmaceutical companies. RxHope® is today's largest, independent, web-based patient-assistance program resource, processing and fulfilling thousands of requests every day. For more information, please visit www.RxHope.com.

LUMIGAN® 0.01% (bimatoprost ophthalmic solution) is used for the treatment of high eye pressure, also called intraocular pressure (IOP), in people with open-angle glaucoma or ocular hypertension.

Important Safety Information


LUMIGAN® 0.01% (bimatoprost ophthalmic solution) has been reported to cause darkening (pigmentation) of eye color, eyelid skin, and eyelashes as well as increased growth of eyelashes. Pigmentation changes can increase as long as LUMIGAN® 0.01% is used. After stopping LUMIGAN® 0.01%, darkening of eye color is likely to be permanent, while darkening of the eyelid skin and eyelash changes may be reversible. The effects of increased darkening beyond 5 years are not known.

When only one eye is treated, there is a possibility of eyelash changes in the eye treated with LUMIGAN® 0.01%. These changes may result in differences between the eyes in eyelash length, thickness, darkness, number of eyelashes, and/or direction of eyelash growth. These changes are usually reversible upon stopping LUMIGAN® 0.01% therapy.

Avoid allowing the tip of the dispensing bottle to touch the eye, anything around the eye, fingers, or any other surface in order to avoid contamination by common bacteria known to cause eye infections. Serious damage to the eye and loss of vision may result from using contaminated solutions.

If you have eye surgery or develop any eye reactions (such as trauma or infection), immediately consult with your physician about continuing the use of LUMIGAN® 0.01%.

If you wear contact lenses, remove them before using LUMIGAN® 0.01%. Then wait 15 minutes after using LUMIGAN® 0.01% before you put your contacts back into your eyes.

The most common side effects are eye redness, growth of eyelashes, and itchy eyes.

Click here for full prescribing information.

This site is intended for US residents only. No information on this site is provided with the intention to give medical advice or instructions on the accurate use of Allergan products. Allergan cannot answer unsolicited emails requesting personal medical advice; visitors should always consult a healthcare professional. Please visit the Allergan site for your country of residence for information concerning Allergan products and services available there.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

 

You are now leaving the LUMIGAN® website. Click OK to continue.